Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 109 results

Search Constraints

Start Over You searched for: Author "Stilgenbauer, Stephan" Remove constraint Author: "Stilgenbauer, Stephan" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
109 results on '"Stilgenbauer, Stephan"'

Search Results

1. Abstract P15: Cross-species DNA methylation profiling of T and B cell populations in T-PLL and B-CLL compared to TCL1 transgenic mouse models

2. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

3. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

4. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

5. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

6. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

7. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

8. Supplementary Table S3 from Discovery of Candidate DNA Methylation Cancer Driver Genes

9. Supplementary Table S1 from Discovery of Candidate DNA Methylation Cancer Driver Genes

10. Data from Discovery of Candidate DNA Methylation Cancer Driver Genes

11. Supplementary Table S2 from Discovery of Candidate DNA Methylation Cancer Driver Genes

12. Supplementary Table S4 from Discovery of Candidate DNA Methylation Cancer Driver Genes

13. Data from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

14. Supplementary Table S3 from Discovery of Candidate DNA Methylation Cancer Driver Genes

15. Data from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

16. Supplementary Figures 1-10 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

17. Supplementary Table 2 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

18. Supplementary Table S5 from Discovery of Candidate DNA Methylation Cancer Driver Genes

19. Supplementary Table 1 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

20. Supplementary Table S2 from Discovery of Candidate DNA Methylation Cancer Driver Genes

21. Supplementary Table 2 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

22. Supplementary Table S6 from Discovery of Candidate DNA Methylation Cancer Driver Genes

23. Data from Discovery of Candidate DNA Methylation Cancer Driver Genes

24. Supplementary Figures 1-10 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

25. Supplementary Table S5 from Discovery of Candidate DNA Methylation Cancer Driver Genes

26. Supplementary Data from Discovery of Candidate DNA Methylation Cancer Driver Genes

27. Supplementary Table S1 from Discovery of Candidate DNA Methylation Cancer Driver Genes

28. Supplementary Table 1 from Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

29. Supplementary Data from Discovery of Candidate DNA Methylation Cancer Driver Genes

30. Supplementary Table S4 from Discovery of Candidate DNA Methylation Cancer Driver Genes

31. Supplementary Table S6 from Discovery of Candidate DNA Methylation Cancer Driver Genes

32. Table S3 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

33. Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax

34. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

35. Table S1 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

36. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

37. Supplementary Figure 2A from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

38. Supplementary Figure 2C from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

39. Figure S3B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

40. Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax

41. Figure S2A from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

42. Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

43. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

44. Table S2, Table S4, Table S6, Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Supplementary Methods from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

45. Table S6 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

46. Table S1 from MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma

47. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

48. Supplementary Figure 1 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

49. Supplementary Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

50. Supplementary Figure 2B from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Catalog

Books, media, physical & digital resources